<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fibrodysplasia ossificans progressiva</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fibrodysplasia ossificans progressiva</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fibrodysplasia ossificans progressiva</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John E Tis, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William A Phillips, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H971180660"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fibrodysplasia ossificans progressiva (FOP; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F135100&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FhZoXfIwGhkfVDgo%2BOyniNWUeGMpcK6DB9K74JFZXtL&amp;TOPIC_ID=120243" target="_blank">MIM #135100</a>; also called myositis ossificans progressiva or "stone man disease") is a rare connective tissue disorder characterized by severe, progressive heterotopic ossification of soft tissues that spans joints and results in an ectopic skeleton [<a href="#rid1">1</a>]. It severely decreases mobility and causes significant disability with no effective treatment.</p><p>The clinical features and treatment of FOP will be reviewed here. Heterotopic ossification as a complication of surgery or trauma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7973.html" rel="external">"Complications of total hip arthroplasty", section on 'Heterotopic ossification'</a> and  <a class="medical medical_review" href="/z/d/html/16732.html" rel="external">"Surgical management of severe lower extremity injury", section on 'Heterotopic ossification'</a> and  <a class="medical medical_review" href="/z/d/html/16732.html" rel="external">"Surgical management of severe lower extremity injury"</a>.)</p><p class="headingAnchor" id="H2377495731"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence is approximately 1 in 2 million with no sex, racial, ethnic, or geographic predisposition [<a href="#rid1">1</a>]. There are no known risk factors.</p><p class="headingAnchor" id="H2886893352"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>FOP is caused by mutations in the <em>ACVR1</em>/<em>ALK2</em> gene on chromosome 2q24, which encodes activin A receptor type I/activin-like kinase 2, a bone morphogenetic protein type I receptor [<a href="#rid2">2</a>]. Most cases are sporadic, but autosomal dominant germline transmission has been reported in a small number of cases.</p><p class="headingAnchor" id="H2884814082"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with FOP generally appear normal at birth except for bilateral malformation of the great toes, which are characteristically short and laterally deviated (hallux valgus); the first metatarsals are malformed and the first toes have an absent or fused interphalangeal joint [<a href="#rid1">1</a>]  (<a class="graphic graphic_picture graphicRef122112" href="/z/d/graphic/122112.html" rel="external">picture 1</a>).</p><p>Variable clinical features of FOP include short, malformed thumbs (in approximately 50 percent), clinodactyly, neck stiffness, and hearing loss (in approximately 50 percent) [<a href="#rid3">3,4</a>].</p><p>Sporadic, painful episodes of rapidly progressive soft tissue swelling ("flare-ups") typically begin during the first decade of life [<a href="#rid4">4-7</a>]. These usually present as nodules on the head or back and occur at a median age of 1.5 years, although 10 percent of patients present with nodules in the neonatal period [<a href="#rid8">8</a>]. The soft tissue swellings may resolve but more often transform skeletal muscles, tendons, ligaments, fascia, and aponeuroses into ribbons, sheets, or plates of heterotopic bone [<a href="#rid9">9</a>]. Flare-ups may be precipitated by soft tissue injury, intramuscular injection, surgical incisions, falls, muscular stretching, or viral illness [<a href="#rid10">10</a>]. They typically begin in the head, neck, and shoulders and progress from cranial to caudal, dorsal to ventral, axial to appendicular, and proximal to distal [<a href="#rid4">4</a>]. The diaphragm, tongue, extraocular muscles, cardiac muscles, and smooth muscles are spared.</p><p>FOP lesions go through predictable stages. Pain, erythema, tenderness, swelling, and warmth are present in the first few weeks. During the intermediate stage, induration increases but pain and erythema improve. During the late stage (after 12 weeks), the nodule hardens with radiographic ossification, but the swelling resolves [<a href="#rid11">11</a>]. In a survey of 44 patients with FOP, the average age of onset of heterotopic ossification was 5 years, restrictive ossification was present in 80 percent of patients by age 7, and 95 percent of patients had severely restricted motion in the upper extremity by age 15 [<a href="#rid12">12</a>].</p><p>The heterotopic bone eventually extends across joints, resulting in progressive and irreversible immobility, weight loss (secondary to ankylosis of the jaw), and thoracic insufficiency syndrome  (<a class="graphic graphic_diagnosticimage graphicRef122114" href="/z/d/graphic/122114.html" rel="external">image 1</a>). Patients are dependent upon diaphragmatic breathing because the diaphragm is spared. Most patients die of respiratory depression or pneumonia. Starvation (related to ankylosis of the jaw) used to be a common cause of death, but modern feeding tubes have made starvation a less common cause of death. (See <a class="local">'Prognosis'</a> below.)</p><p class="headingAnchor" id="H2384507976"><span class="h1">LABORATORY FEATURES</span><span class="headingEndMark"> — </span>Biochemical studies (eg, serum alkaline phosphatase, parathyroid hormone level, renal function, urinary calcium, and phosphate) are usually normal [<a href="#rid13">13</a>]. Alkaline phosphatase is elevated in some patients during new episodes of heterotopic ossification formation [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H1098993347"><span class="h1">RADIOGRAPHIC FINDINGS</span><span class="headingEndMark"> — </span>Characteristic radiographic features of FOP include joint malformations, particularly of the great toe (eg, bilateral hallux valgus deformity, malformed first metatarsal, absent or fused interphalangeal joint), and soft tissue ossification [<a href="#rid3">3</a>]. Preosseous lesions and early heterotopic ossification are visible on bone scan, computed tomography, or magnetic resonance imaging before radiographs [<a href="#rid13">13,15</a>].</p><p>Variable radiographic features of FOP include proximal medial tibial osteochondromas (approximately 90 percent); orthotopic fusions of the posterior elements of the cervical spine (approximately 80 percent); broad, short femoral necks (approximately 50 percent); and malformations of the thumbs (approximately 50 percent) [<a href="#rid1">1,3</a>].</p><p class="headingAnchor" id="H1766879948"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>FOP is a clinical diagnosis that is confirmed with molecular genetics. FOP should be suspected in children with hallux valgus, progressive soft tissue swelling, and nodules on the head or back. Biopsy of the soft tissue lesions may precipitate a flare-up and should be avoided [<a href="#rid10">10,16</a>].</p><p>Definitive diagnosis requires genetic confirmation with specific molecular genetic studies that detect missense mutations or "in frame" deletions in the protein-encoding region of the <em>ACVR1</em> gene [<a href="#rid3">3,8,17</a>]. Consultation with a clinical geneticist is recommended before genetic testing [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3733329594"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of FOP includes other conditions associated with malformed great toes, soft tissue swelling, or heterotopic ossification. The <strong>combination </strong>of these three findings generally distinguishes FOP from these conditions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions with malformed great toes</strong> – Other conditions associated with malformed great toes include isolated congenital malformations, brachydactyly, synostosis and symphalangism syndromes (ie, fusion of bones and joints of the fingers or toes), and juvenile bunions [<a href="#rid3">3,18</a>]. In contrast to these conditions, children with FOP often have other skeletal malformations (eg, malformations of the thumb, cervical spine abnormalities, osteochondromas of the proximal medial tibia), rapidly progressive soft tissue swelling, and heterotopic ossification [<a href="#rid3">3</a>]. Juvenile bunions are not present in the neonatal period, whereas the hallux valgus deformity in FOP is present at birth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions with femoral or tibial osteochondromas</strong> – Distal femoral and proximal tibial osteochondromas also may occur in patients with hereditary multiple osteochondromas [<a href="#rid19">19</a>]. However, patients with hereditary multiple osteochondromas do not typically have malformed great toes or episodic flare-ups. (See  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents", section on 'Osteochondroma and hereditary multiple osteochondromas'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions with heterotopic ossification</strong> – Heterotopic ossification also may occur in children with progressive osseous heteroplasia (POH; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F166350&amp;token=87jLzclRwWxNoI%2BQq5Gg75P36IY99OM0UzMb0LYRjg1ByD9QFxvSn55ZoYdH7lds&amp;TOPIC_ID=120243" target="_blank">MIM #166350</a>), a rare genetic condition characterized by cutaneous ossification that progresses to involve subcutaneous and deep connective tissues [<a href="#rid1">1</a>]. POH is distinguished from FOP by the sites of ossification and lack of great toe malformation and "flare-ups." Although acquired heterotopic ossification also occurs at sites of trauma, it is rare in young children and not usually associated with great toe malformation or flare-ups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions with rapidly progressive soft tissue lesions</strong> – Rapidly progressive soft tissue lesions may raise concern for neoplasms and other tumors (eg, soft tissue sarcoma, osteosarcoma, aggressive juvenile fibromatosis [extra-abdominal desmoid tumors]) or lymphedema [<a href="#rid3">3,19</a>]. However, the sudden onset and rapid change in size and shape (often within hours) of soft tissue lesions associated with FOP is not characteristic of these conditions. Evaluation of the great toes and consideration of FOP should be considered before biopsy is performed. (See  <a class="medical medical_review" href="/z/d/html/14259.html" rel="external">"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">"Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis", section on 'Clinical presentation'</a> and  <a class="medical medical_review" href="/z/d/html/7746.html" rel="external">"Desmoid tumors: Epidemiology, molecular pathogenesis, clinical presentation, diagnosis, and local therapy", section on 'Clinical presentation and diagnosis'</a>.)</p><p></p><p class="headingAnchor" id="H796728752"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of FOP is predominantly supportive and focuses on prevention of flare-ups, patient and family education and counseling, and improved quality of life. Several drugs are in clinical trials to determine if they are effective in decreasing heterotopic bone formation in patients with FOP: <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">palovarotene</a>, REGN 2477, and rapamycin. None is approved by the US Food and Drug Administration (FDA) or the European Medicines Agency, but palovarotene has been approved in Canada.</p><p>Children with FOP should be managed in consultation with an expert in FOP. Consensus guidelines from the International Clinical Council on FOP (ICC) and consultants for the medical management of FOP are available on the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ifopa.org%2Ffor_medical_professionals&amp;token=xFYUVan6gjv%2B4sGZwbFp8mwvcnDsEqkg0Wa%2FYwSKC6LiwiKnsr0j0hG89tClWnyCnoAjDk52jYetP5qGmBQ%2Fpg%3D%3D&amp;TOPIC_ID=120243" target="_blank">International Fibrodysplasia Ossificans Progressiva Association website</a> [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3944321655"><span class="h2">Prevention of flare-ups</span></p><p class="headingAnchor" id="H1900947912"><span class="h3">Avoid biopsies, surgery, and trauma</span><span class="headingEndMark"> — </span>Biopsies and removal of lesions are contraindicated because they precipitate aggressive ossific reaction in the soft tissues. Similarly, correction of fixed deformities often leads to further ossification and loss of motion [<a href="#rid4">4</a>].</p><p>Attempts at resecting the ankylosis across the jaw have been unsuccessful and are not recommended [<a href="#rid20">20,21</a>]. Scoliosis is usually not addressed surgically because spinal fusion, especially posterior fusion, in younger patients generally results in worsening of the curve [<a href="#rid22">22</a>]. However, rapidly progressive lumbar curves in children younger than five years of age may warrant anterior, with or without posterior, surgical treatment to prevent progression [<a href="#rid23">23</a>].</p><p>FOP patients have increased anesthetic risks due to restrictive lung disease, fused cervical vertebrae, restricted oral access, and abnormal cardiac conduction. Considerations for general anesthesia in patients with FOP are provided in the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iccfop.org%2Fdvlp%2Fwp-content%2Fuploads%2F2020%2F03%2FGuidelines_January-2020.pdf&amp;token=91aVabNGunX2CTxIKBpcIn%2FtOwVD1mq0dvFb2%2BjNcqzYmtEWJYzHdc8ReYKIAM3%2FyqeA6VSvXtiEWDyqxOroSqAzMVn%2BCPaHLtYMkKopvdGb7NwDNhVTAAjJTDPT%2Boh2&amp;TOPIC_ID=120243" target="_blank">ICC guidelines</a> [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H779377350"><span class="h3">Prevention of falls</span><span class="headingEndMark"> — </span>Falls may lead to injury and painful flare-ups. In a survey of 135 patients with FOP, 81 percent reported an injury related to a fall; two-thirds of falls led to painful flare-ups and one-half of falls led to permanent disability [<a href="#rid24">24</a>]. Strategies to prevent falls include limiting high-risk activities, installing handholds and other safety measures in living spaces, and the use of headgear [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H3010937938"><span class="h3">Prevention of viral illnesses</span><span class="headingEndMark"> — </span>Viral illnesses can cause flare-ups of FOP [<a href="#rid25">25</a>]. Strategies to prevent viral illness include frequent washing of the hands with soap and water or an alcohol-based hand sanitizer; not touching the eyes, nose, or mouth with hands unless the hands are washed; and limiting contact with people who are sick [<a href="#rid16">16,26</a>]. (See  <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection", section on 'Hand hygiene'</a>.)</p><p class="headingAnchor" id="H1386838778"><span class="h3">Immunizations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza vaccine</strong> – Influenza infections may trigger flare-ups of FOP [<a href="#rid25">25</a>]. The ICC suggests annual influenza vaccination for patients with FOP, with specific caveats [<a href="#rid16">16</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="drug drug_pediatric" data-topicid="12941" href="/z/d/drug information/12941.html" rel="external">live attenuated influenza vaccine</a> (LAIV) is not recommended because it may precipitate a flare-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="drug drug_pediatric" data-topicid="12940" href="/z/d/drug information/12940.html" rel="external">inactivated influenza vaccine</a> (IIV) should be administered according to a modified protocol in which it is administered subcutaneously rather than intramuscularly.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Influenza vaccine should <strong>not</strong> be administered during a flare-up or within six to eight weeks of a flare-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Influenza vaccine should <strong>not</strong> be administered near a joint or muscle group that has been affected by FOP.</p><p></p><p class="bulletIndent1">Close contacts of patients with FOP also should receive annual influenza immunization. The ICC recommends that close contacts of patients with FOP receive IIV rather than LAIV [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other vaccines</strong> – Recommendations for other vaccines are individualized according to the potential benefits and harms for the particular vaccine in a particular patient. Factors to be considered include the risk of precipitating a flare-up, the risk of exposure to a vaccine-preventable disease, and the number of doses of vaccines received before the child was diagnosed with FOP. Detailed recommendations are provided in the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.iccfop.org%2Fdvlp%2Fwp-content%2Fuploads%2F2020%2F03%2FGuidelines_January-2020.pdf&amp;token=91aVabNGunX2CTxIKBpcIn%2FtOwVD1mq0dvFb2%2BjNcqzYmtEWJYzHdc8ReYKIAM3%2FyqeA6VSvXtiEWDyqxOroSqAzMVn%2BCPaHLtYMkKopvdGb7NwDNhVTAAjJTDPT%2Boh2&amp;TOPIC_ID=120243" target="_blank">ICC guidelines</a> [<a href="#rid16">16</a>]. In general:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaccines should <strong>not</strong> be administered during a flare-up or within six to eight weeks of a flare-up.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaccines should <strong>not</strong> be administered near a joint or muscle group that has been affected by FOP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diphtheria- or tetanus-toxoid containing vaccines (eg, the combination diphtheria, tetanus, and acellular pertussis vaccine) may cause flare-ups, heterotopic ossification, and permanent loss of joint motion [<a href="#rid16">16,27</a>]. They should be avoided in children with FOP unless indicated to prevent life-threatening illness [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2">Flare-ups also may be caused by vaccines that contain components of diphtheria and tetanus as protein conjugates (eg, <em>Haemophilus influenzae</em> type b [Hib] vaccine; meningococcal serogroups A, C, W, and Y vaccine; pneumococcal conjugate vaccine; combination Hib and meningococcal serogroup C vaccine). The safety of these vaccines for patients with FOP is uncertain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intramuscular (IM) injections are <strong>contraindicated</strong> because they precipitate flare-ups.</p><p></p><p class="bulletIndent2">Whether vaccines that are typically administered IM are effective when administered subcutaneously is uncertain. There is some evidence to effectiveness for hepatitis A and B vaccines when administered subcutaneously [<a href="#rid28">28,29</a>], but evidence for other vaccines that are typically administered IM (eg, human papillomavirus vaccine, <a class="drug drug_pediatric" data-topicid="99754" href="/z/d/drug information/99754.html" rel="external">meningococcal serogroup B vaccine</a>) is lacking.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Subcutaneous administration is routinely recommended for the following vaccines, which are generally considered safe for patients with FOP: measles, mumps, and rubella (MMR) vaccine; the <a class="drug drug_pediatric" data-topicid="13006" href="/z/d/drug information/13006.html" rel="external">varicella vaccine</a>; the combination MMR and varicella vaccine; and inactivated <a class="drug drug_pediatric" data-topicid="12967" href="/z/d/drug information/12967.html" rel="external">poliovirus vaccine</a> [<a href="#rid16">16,30</a>].</p><p></p><p class="headingAnchor" id="H4159620571"><span class="h3">Glucocorticoid prophylaxis</span><span class="headingEndMark"> — </span>A short course of glucocorticoids may be warranted to prevent flare-ups within 24 hours of severe soft tissue trauma or emergency, elective, major, or minor surgery (eg, appendectomy, dental surgery) [<a href="#rid16">16</a>]. The ICC suggests <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> 1 to 2 mg/kg orally once or twice per day (maximum daily dose 100 mg) for three to four days [<a href="#rid16">16</a>]. Equivalent doses of other oral glucocorticoids may be administered. Although glucocorticoid prophylaxis has not been studied systematically in patients with FOP, inflammation plays in important role in the development of FOP flare-ups [<a href="#rid31">31,32</a>].</p><p class="headingAnchor" id="H879360333"><span class="h2">Symptomatic management of early lesions</span></p><p class="headingAnchor" id="H2755454709"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>A short course of glucocorticoids may be warranted for the early symptomatic management of flare-ups affecting the jaw, submandibular area, or major joints (eg, hip); consultation with an expert in FOP is recommended for patients with submandibular flare-ups. When administered within the first 24 hours of a flare-up, a short course of glucocorticoids may reduce inflammation and tissue edema and prevent some symptoms. Glucocorticoids usually are not used in the symptomatic management of flare-ups of the neck or trunk because these flare-ups are typically prolonged and recurrent [<a href="#rid33">33</a>].</p><p>When glucocorticoids are used, the ICC suggests <a class="drug drug_pediatric" data-topicid="12725" href="/z/d/drug information/12725.html" rel="external">prednisone</a> 1 to 2 mg/kg orally once or twice per day (maximum daily dose 100 mg) for three to four days [<a href="#rid16">16</a>]. Equivalent doses of other oral glucocorticoids may be administered.</p><p>After discontinuation of the glucocorticoid, or if glucocorticoids are not used, topical or systemic nonsteroidal anti-inflammatory medication (eg, <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a>) may be used for symptomatic management during the remainder of the flare-up. Local application of cool packs also may be helpful.</p><p>The use of glucocorticoids in the symptomatic management of FOP flare-ups is based upon the importance of inflammation in FOP flare-ups [<a href="#rid31">31,32</a>]. In a survey, 75 percent of 500 patients used short-term glucocorticoids for flare-ups of the limbs; among these, 31 percent reported that glucocorticoids always improved symptoms, and 55 percent reported that they occasionally did; 12 percent reported that they had complete resolution of a flare-up with glucocorticoids [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H3070299685"><span class="h3">Ibuprofen</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_pediatric" data-topicid="13371" href="/z/d/drug information/13371.html" rel="external">ibuprofen</a> (or other prostaglandin inhibitors) may prevent heterotopic ossification because inflammatory prostaglandins are thought to stimulate induction of heterotopic bone [<a href="#rid34">34-36</a>].</p><p></p><p class="headingAnchor" id="H1675141582"><span class="h3">Palovarotene</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> is a selective retinoic acid receptor gamma agonist [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H1878504298"><span class="h4">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> is available in the United States and Canada for the reduction of heterotopic ossification in females ≥8 years of age and males ≥10 years of age with FOP; it is available for chronic treatment with dose escalations for flare-ups/substantial trauma (chronic/flare-up regimen) or for treatment of flare-ups only.</p><p>The safety and potential efficacy of <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">palovarotene</a> were demonstrated in a randomized placebo-controlled trial in 40 patients with FOP experiencing a flare-up. This study revealed a promising but nonsignificant decrease in heterotopic ossification formation [<a href="#rid38">38,39</a>]. In a subsequent, multicenter, open-label, single-arm trial of the chronic/flare-up regimen, palovarotene reduced the mean annualized new heterotopic ossification volume by 60 percent among 97 participants (mean age 15 years) available for the 18-month visit compared with 101 untreated patients (mean age 17 years) from a natural history study [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H1520900744"><span class="h4">Contraindications and precautions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy – Including pregnant people, people who are breastfeeding, and those of childbearing potential.</p><p></p><p class="bulletIndent2">Exceptions include meeting all conditions of pregnancy prevention or there is no risk of pregnancy due to physical limitations.</p><p></p><p class="bulletIndent2">As with other retinoic acid derivatives, <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">palovarotene</a> is teratogenic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known hypersensitivity to retinoids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Growing children with open growth plates – <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> may cause premature closure of the physeal growth plates. In clinical trials, 24 percent of participants &lt;18 years of age with open epiphyses had premature physeal closure.</p><p></p><p class="bulletIndent2">Before initiation of <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">palovarotene</a>, growing children should undergo baseline evaluation of linear growth (plotting of height on standard growth curves), sexual maturity  (<a class="graphic graphic_picture graphicRef72038 graphicRef79782 graphicRef80005" href="/z/d/graphic/72038.html" rel="external">picture 2A-C</a>), and skeletal maturity (hand/wrist and knee radiographs). Reassessment of linear growth and radiographic evaluation of skeletal maturity is recommended every three months until patients reach skeletal maturity or final adult height.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatic and kidney impairment – <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> has not been studied in patients with moderate or severe hepatic impairment or severely reduced glomerular filtration rate and is not recommended for these patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CYP3A4 inhibitors and inducers – <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> undergoes hepatic metabolism by cytochrome P450 3A4 (CYP3A4). Use with CYP3A4 inhibitors may increase toxicity and is not recommended; however, dose adjustments are available for use with moderate CYP3A4 inhibitors if concurrent use is unavoidable. Use with moderate or strong CYP3A4 inducers is not recommended due to potential for decreased efficacy. Lists of CYP3A4 inhibitors and inducers are provided in the table  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tetracyclines [<a href="#rid41">41</a>] – Cases of pseudotumor cerebri have been reported with concurrent use of tetracyclines and systemic retinoic acid derivatives. <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> prescribing information recommends against coadministration [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other oral retinoids (including vitamin A) should be avoided due to risk for vitamin A toxicity.</p><p></p><p class="headingAnchor" id="H690427964"><span class="h4">Administration</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> should be taken with food and ideally at the same time each day. The capsules may be swallowed whole or the contents may be emptied onto a teaspoon of soft food (eg, applesauce, yogurt) and consumed immediately.</p><p>Among those who could be pregnant, a pregnancy test should be obtained before drug administration, within one week of initiation, and periodically during treatment.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic regimen</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥14 years – 5 mg orally once daily</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age 8 to &lt;14 years (females) or age 10 to &lt;14 years (males):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight 10 to &lt;20 kg – 2.5 mg orally once daily</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight 20 to &lt;40 kg – 3 mg orally once daily</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight 40 to &lt;60 kg – 4 mg orally once daily</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight ≥60 kg – 5 mg orally once daily</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Flare-up regimen</strong> – Begin the flare-up regimen at the onset of the first flare-up symptom or as soon as possible after a substantial high-risk traumatic event likely to lead to a flare-up (eg, fall, substantial contusion, surgery). For patients who are receiving chronic <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">palovarotene</a>, the chronic regimen should be discontinued when the flare-up regimen is initiated and resumed when the flare-up regimen is completed.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥14 years – 20 mg orally once daily for four weeks, followed by 10 mg orally once daily for eight weeks</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age 8 to &lt;14 years (females) or age 10 to &lt;14 years (males)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight 10 to &lt;20 kg – 10 mg orally once daily for four weeks, followed by 5 mg orally once daily for eight weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight 20 to &lt;40 kg – 12.5 mg orally once daily for four weeks, followed by 6 mg orally once daily for eight weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight 40 to &lt;60 kg – 15 mg orally once daily for four weeks, followed by 7.5 mg orally once daily for eight weeks</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Weight ≥60 kg – 20 mg orally once daily for four weeks, followed by 10 mg orally once daily for eight weeks</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjustments to flare-up regimen</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent symptoms – If symptoms persist, treatment with the lower dose (ie, that used for weeks 5 through 12) may be extended in four-week intervals. A maximum number of four-week intervals has not been established. We make this determination on a case-by-case basis and extend the treatment as the patient tolerates and the symptoms dictate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>New or worsening flare-up – If the patient has a new flare-up at a different location or marked worsening of the original flare-up, the 12-week flare-up regimen should be restarted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects reported among &gt;20 percent of clinical trial participants include dry skin (78 percent), dry lips (55 percent), alopecia (41 percent), pruritus (40 percent), erythema (32 percent), skin exfoliation (31 percent), and rash (30 percent) [<a href="#rid43">43</a>]. Other adverse effects include dry eyes, sensitivity to sunlight, hearing and vision impairment, mouth ulcers, paronychia, pancreatitis, and hypertriglyceridemia [<a href="#rid33">33,37,44,45</a>]. Refer to the <a class="external" href="/drug-interactions">drug interactions program</a> or local prescribing information for dosage reductions for intolerable adverse reactions.</p><p></p><p class="headingAnchor" id="H2774274306"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>As the molecular mechanisms of FOP become better known, other therapeutic agents have shown promise [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>REGN-2477</strong> – REGN-2477, an activin A antibody, has shown promising preclinical results and is in late clinical trials in the United States and Europe [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03188666&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiQeHSkH5mIOh4EH9h82zzGkgKWqHbZwVDWC8hW5rPMkCQ%3D%3D&amp;TOPIC_ID=120243" target="_blank">NCT03188666</a>] [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rapamycin</strong> – Rapamycin, an mTORC1 inhibitor that is a commonly used immunosuppressant, has shown mixed results [<a href="#rid49">49,50</a>] and is in late clinical trials in Japan [<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcenter6.umin.ac.jp%2Fcgi-open-bin%2Fctr_e%2Fctr_view.cgi%3Frecptno%3DR000032495&amp;token=tMGqeicMrgCHxzbPdz4kLaVPvrKbioG2TjML2xmGEOFctH%2BssK39z3VLtZaK75r2zwP2EWCaMHClkxAe%2FeA3UpwXdZqY2hhXtJeEwjVJaxo%3D&amp;TOPIC_ID=120243" target="_blank">UMIN000028429</a>] [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-interleukin agents</strong> – In a case report, anti-interleukin agents (<a class="drug drug_pediatric" data-topicid="13251" href="/z/d/drug information/13251.html" rel="external">anakinra</a> and <a class="drug drug_pediatric" data-topicid="17066" href="/z/d/drug information/17066.html" rel="external">canakinumab</a>) appeared to be helpful in decreasing the frequency of flare-ups [<a href="#rid51">51</a>], but anti-interleukin therapy remains investigational.</p><p></p><p class="headingAnchor" id="H2418043619"><span class="h2">Preventive dental care</span><span class="headingEndMark"> — </span>Preventive dental care is a crucial component of the management of FOP and should begin as soon as possible. Preventive dental care is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6279.html" rel="external">"Preventive dental care and counseling for infants and young children"</a>.)</p><p>Consultation with a dental professional with expertise in FOP is recommended before any dental procedure [<a href="#rid16">16</a>]. Injections of local anesthetic for dental procedures should be avoided [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H173381603"><span class="h2">Hearing evaluation</span><span class="headingEndMark"> — </span>Children with FOP are at increased risk for conductive hearing loss. They should undergo evaluation for hearing impairment with audiometry at least every other year [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/6297.html" rel="external">"Hearing loss in children: Screening and evaluation", section on 'Formal audiology'</a>.)</p><p class="headingAnchor" id="H201917152"><span class="h2">Respiratory health</span><span class="headingEndMark"> — </span>Chest deformity and scoliosis in patients with FOP may decrease respiratory capacity. Respiratory health can be maintained in patients with FOP through active respiratory activity (eg, singing, incentive spirometry, peak flow whistles) [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H701213533"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most patients require a wheelchair by age 20 years [<a href="#rid1">1</a>]. Alternative feeding methods (eg, feeding tubes, gastrostomy tubes) have prolonged the life span of patients with ankylosis of the jaw. In a review of information from two large registries, the median lifespan was approximately 40 years; the most common causes of death were thoracic insufficiency (54 percent) and pneumonia (15 percent) [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H4122392047"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – Fibrodysplasia ossificans progressiva (FOP; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F135100&amp;token=87jLzclRwWxNoI%2BQq5Gg7%2FhZoXfIwGhkfVDgo%2BOyniNWUeGMpcK6DB9K74JFZXtL&amp;TOPIC_ID=120243" target="_blank">MIM #135100</a>) is a rare connective tissue disorder caused by mutations in the <em>ACVR1</em>/<em>ALK2</em> gene, which encodes a bone morphogenetic protein receptor. Most cases are sporadic. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Characteristic clinical features include bilateral malformation of the great toes at birth (they are short and laterally deviated [ie, hallux valgus])  (<a class="graphic graphic_picture graphicRef122112" href="/z/d/graphic/122112.html" rel="external">picture 1</a>); sporadic, painful episodes of rapidly progressive soft-tissue swelling ("flare-ups"); and heterotopic ossification that eventually spans joints, resulting in progressive and irreversible immobility, weight loss, and thoracic insufficiency syndrome. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Flare-ups usually begin in the first decade of life, presenting as nodules on the head or back. They can be precipitated by soft tissue injury, intramuscular (IM) injection, surgical incision, falls, muscular stretching, or viral illness. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – FOP should be suspected in children with hallux valgus, progressive soft tissue swelling, and nodules on the head or back. Definitive diagnosis requires molecular genetic studies that detect missense mutations or "in frame" deletions in the protein-encoding region of the <em>ACVR1</em> gene. Biopsy of soft tissue lesions may precipitate a flare-up and should be avoided. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of FOP includes other conditions associated with malformed great toes, soft tissue swelling, or heterotopic ossification. The combination of these three findings generally distinguishes FOP from these conditions. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Management is predominantly supportive and focuses on prevention of flare-ups, patient and family education and counseling, and improved quality of life. <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> is a selective retinoic-acid receptor gamma agonist that inhibits heterotopic ossification and shows clinical promise. It is not widely available. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention of flare-ups</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Biopsies, surgery, and trauma should be avoided if possible. (See <a class="local">'Avoid biopsies, surgery, and trauma'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Limiting activities with a high-risk of falls, installing handholds and other safety measures, and use of headgear may prevent falls or severe trauma from falls. (See <a class="local">'Prevention of falls'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IM injection of vaccines is contraindicated. Additional immunization precautions are discussed above. (See <a class="local">'Immunizations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Use of </strong><strong>palovarotene</strong> – <a class="drug drug_pediatric" data-topicid="139381" href="/z/d/drug information/139381.html" rel="external">Palovarotene</a> is a selective retinoic-acid receptor gamma agonist that inhibits heterotopic ossification. It is available for the reduction of heterotopic ossification in females ≥8 years of age and males ≥10 years of age with FOP.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preventive health maintenance</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Preventive dental care is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6279.html" rel="external">"Preventive dental care and counseling for infants and young children"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Children with FOP should undergo evaluation for hearing impairment with audiometry at least every other year. (See <a class="local">'Hearing evaluation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Respiratory health can be maintained through active respiratory activity (eg, singing, incentive spirometry, peak flow whistles). (See <a class="local">'Respiratory health'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis 2011; 6:80.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009; 30:379.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008; 121:e1295.</a></li><li><a class="nounderline abstract_t">Rogers JG, Geho WB. Fibrodysplasia ossificans progressiva. A survey of forty-two cases. J Bone Joint Surg Am 1979; 61:909.</a></li><li><a class="nounderline abstract_t">Kartal-Kaess M, Shore EM, Xu M, et al. Fibrodysplasia ossificans progressiva (FOP): watch the great toes! Eur J Pediatr 2010; 169:1417.</a></li><li><a class="nounderline abstract_t">Mantick N, Bachman E, Baujat G, et al. The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva. Bone 2018; 109:285.</a></li><li><a class="nounderline abstract_t">Baujat G, Choquet R, Bouée S, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis 2017; 12:123.</a></li><li><a class="nounderline abstract_t">Piram M, Le Merrer M, Bughin V, et al. Scalp nodules as a presenting sign of fibrodysplasia ossificans progressiva: a register-based study. J Am Acad Dermatol 2011; 64:97.</a></li><li><a class="nounderline abstract_t">Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment. J Bone Miner Res 2016; 31:650.</a></li><li><a class="nounderline abstract_t">Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005; 116:e654.</a></li><li class="breakAll">Orthopaedic-related syndromes. In: Tachdjian's Procedures in Pediatric Orthopaedics: From the Texas Scottish Rite Hospital for Children, Herring JA (Ed), WB Saunders Company, Philadelphia, PA 2002. Vol 3rd, p.1632.</li><li><a class="nounderline abstract_t">Cohen RB, Hahn GV, Tabas JA, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 1993; 75:215.</a></li><li><a class="nounderline abstract_t">Verma AK, Aga P, Singh SK, Singh R. The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited. BMJ Case Rep 2012; 2012.</a></li><li><a class="nounderline abstract_t">Al Kaissi A, Kenis V, Ben Ghachem M, et al. The Diversity of the Clinical Phenotypes in Patients With Fibrodysplasia Ossificans Progressiva. J Clin Med Res 2016; 8:246.</a></li><li><a class="nounderline abstract_t">Trikha V, Kumar R, Khan SA, Rastogi S. Characteristic appearance on bone scintigraphy of a 'stone man'. Clin Nucl Med 2005; 30:517.</a></li><li class="breakAll">The International Clinical Council on FOP (ICC) and Consultants. The medical management of fibrodysplasia ossificans progressiva: Current treatment considerations. March 2019. Available at: https://www.ifopa.org/for_medical_professionals (Accessed on February 04, 2021).</li><li><a class="nounderline abstract_t">Di Rocco M, Baujat G, Bertamino M, et al. International physician survey on management of FOP: a modified Delphi study. Orphanet J Rare Dis 2017; 12:110.</a></li><li><a class="nounderline abstract_t">Towler OW, Shore EM, Xu M, et al. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call. Eur J Med Genet 2017; 60:399.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 2008; 22:191.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Glaser DL, Shore EM, et al. The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005; 3:183.</a></li><li><a class="nounderline abstract_t">Eekhoff EMW, Netelenbos JC, de Graaf P, et al. Flare-Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]-NaF PET/CT Study and a Systematic Review. JBMR Plus 2018; 2:55.</a></li><li><a class="nounderline abstract_t">Shah PB, Zasloff MA, Drummond D, Kaplan FS. Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 1994; 76:1442.</a></li><li><a class="nounderline abstract_t">Moore RE, Dormans JP, Drummond DS, et al. Chin-on-chest deformity in patients with fibrodysplasia ossificans progressiva. A case series. J Bone Joint Surg Am 2009; 91:1497.</a></li><li><a class="nounderline abstract_t">Glaser DL, Rocke DM, Kaplan FS. Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 1998; :110.</a></li><li><a class="nounderline abstract_t">Scarlett RF, Rocke DM, Kantanie S, et al. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res 2004; :275.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Influenza. Preventive steps. Available at: https://www.cdc.gov/flu/prevent/prevention.htm (Accessed on May 28, 2019).</li><li><a class="nounderline abstract_t">Lanchoney TF, Cohen RB, Rocke DM, et al. Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr 1995; 126:762.</a></li><li><a class="nounderline abstract_t">Carpenter SL, Soucie JM, Presley RJ, et al. Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis. Haemophilia 2015; 21:e39.</a></li><li><a class="nounderline abstract_t">Ragni MV, Lusher JM, Koerper MA, et al. Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia. Haemophilia 2000; 6:98.</a></li><li class="breakAll">Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on May 16, 2019).</li><li><a class="nounderline abstract_t">Kaplan FS, Pignolo RJ, Shore EM. Granting immunity to FOP and catching heterotopic ossification in the Act. Semin Cell Dev Biol 2016; 49:30.</a></li><li><a class="nounderline abstract_t">Convente MR, Chakkalakal SA, Yang E, et al. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva. J Bone Miner Res 2018; 33:269.</a></li><li><a class="nounderline abstract_t">Kitoh H. Clinical Aspects and Current Therapeutic Approaches for FOP. Biomedicines 2020; 8.</a></li><li><a class="nounderline abstract_t">Convente MR, Wang H, Pignolo RJ, et al. The immunological contribution to heterotopic ossification disorders. Curr Osteoporos Rep 2015; 13:116.</a></li><li><a class="nounderline abstract_t">Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5:1418.</a></li><li><a class="nounderline abstract_t">Weinreb M, Suponitzky I, Keila S. Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 1997; 20:521.</a></li><li><a class="nounderline abstract_t">Hoy SM. Palovarotene: First Approval. Drugs 2022; 82:711.</a></li><li><a class="nounderline abstract_t">Pignolo RJ, Baujat G, Hsiao EC, et al. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial. J Bone Miner Res 2022; 37:1891.</a></li><li class="breakAll">ClinicalTrials.gov. An open-label extension study of palovarotene treatment in fibrodysplasia ossificans progressiva (FOP).  NCT02279095. https://clinicaltrials.gov/ct2/show/NCT02279095 (Accessed on August 10, 2022).</li><li><a class="nounderline abstract_t">Pignolo RJ, Hsiao EC, Al Mukaddam M, et al. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP). J Bone Miner Res 2023; 38:381.</a></li><li><a class="nounderline abstract_t">Caruana DM, Wylie G. 'Washout' period for oral tetracycline antibiotics prior to systemic isotretinoin. Br J Dermatol 2016; 174:929.</a></li><li class="breakAll">Palovarotene capsule. US Food and Drug Administration (FDA) approved product information. Revised August 24, 2023. US National Library of Medicine. www.dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on October 19, 2023).</li><li class="breakAll">Sohonos (palovarotene) capsules. Canadian product monograph. Mississauga, Ontario: Ipsen Biopharmaceuticals Canada Inc; 2022. Available at: https://pdf.hres.ca/dpd_pm/00064435.PDF (Accessed on August 10, 2022).</li><li><a class="nounderline abstract_t">Opel D, Kramer ON, Chevalier M, et al. Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. Br J Dermatol 2017; 177:960.</a></li><li><a class="nounderline abstract_t">Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur Respir J 2012; 40:306.</a></li><li><a class="nounderline abstract_t">Meng X, Wang H, Hao J. Recent progress in drug development for fibrodysplasia ossificans progressiva. Mol Cell Biochem 2022; 477:2327.</a></li><li><a class="nounderline abstract_t">Hatsell SJ, Idone V, Wolken DM, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med 2015; 7:303ra137.</a></li><li><a class="nounderline abstract_t">Hino K, Ikeya M, Horigome K, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A 2015; 112:15438.</a></li><li><a class="nounderline abstract_t">Hino K, Horigome K, Nishio M, et al. Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest 2017; 127:3339.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Zeitlin L, Dunn SP, et al. Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases. Bone 2018; 109:281.</a></li><li><a class="nounderline abstract_t">Haviv R, Moshe V, De Benedetti F, et al. Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome? Pediatr Rheumatol Online J 2019; 17:84.</a></li><li><a class="nounderline abstract_t">Luchetti W, Cohen RB, Hahn GV, et al. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81:21.</a></li><li><a class="nounderline abstract_t">Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2010; 92:686.</a></li></ol></div><div id="topicVersionRevision">Topic 120243 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22133093" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fibrodysplasia ossificans progressiva: clinical and genetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19085907" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450872" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Early diagnosis of fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/113413" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fibrodysplasia ossificans progressiva. A survey of forty-two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20577760" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fibrodysplasia ossificans progressiva (FOP): watch the great toes!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28866367" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The FOP Connection Registry: Design of an international patient-sponsored registry for Fibrodysplasia Ossificans Progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28666455" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21055844" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Scalp nodules as a presenting sign of fibrodysplasia ossificans progressiva: a register-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27025942" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230464" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230464" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423182" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22843760" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26858800" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The Diversity of the Clinical Phenotypes in Patients With Fibrodysplasia Ossificans Progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965336" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characteristic appearance on bone scintigraphy of a 'stone man'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965336" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Characteristic appearance on bone scintigraphy of a 'stone man'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28606101" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : International physician survey on management of FOP: a modified Delphi study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28473268" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18328989" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The phenotype of fibrodysplasia ossificans progressiva</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30283890" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Flare-Up After Maxillofacial Surgery in a Patient With Fibrodysplasia Ossificans Progressiva: An [18F]-NaF PET/CT Study and a Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7929490" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Spinal deformity in patients who have fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487531" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chin-on-chest deformity in patients with fibrodysplasia ossificans progressiva. A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577417" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Catastrophic falls in patients who have fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232462" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232462" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7752003" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25381731" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hepatitis B vaccination is effective by subcutaneous route in children with bleeding disorders: a universal data collection database analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781196" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781196" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Safety and immunogenicity of subcutaneous hepatitis A vaccine in children with haemophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26706149" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Granting immunity to FOP and catching heterotopic ossification in the Act.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28986986" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887348" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical Aspects and Current Therapeutic Approaches for FOP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25687936" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The immunological contribution to heterotopic ossification disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10581086" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177865" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35384641" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Palovarotene: First Approval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35854638" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35854638" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36583535" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575081" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : 'Washout' period for oral tetracycline antibiotics prior to systemic isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575081" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : 'Washout' period for oral tetracycline antibiotics prior to systemic isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575081" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 'Washout' period for oral tetracycline antibiotics prior to systemic isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27893168" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282548" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Randomised controlled trial for emphysema with a selective agonist of theγ-type retinoic acid receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35536530" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recent progress in drug development for fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26333933" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26621707" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28758906" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241828" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Acute and chronic rapamycin use in patients with Fibrodysplasia Ossificans Progressiva: A report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31864380" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8850477" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194327" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
